Developing new drugs to target a specific gene in colorectal cancer.
The Development of First-in-Class Inhibitors of Oncogenic CHD1L for the Treatment of Colorectal Cancer.
This study is looking at a gene called CHD1L to find new treatments for people with metastatic colorectal cancer, which is a tough form of the disease, by testing ways to block this gene's activity using tumor samples from patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10830997 on NIH RePORTER |
What this research studies
This research focuses on colorectal cancer, particularly the metastatic form, which has a very low survival rate. The team is investigating a gene called CHD1L that plays a crucial role in the progression of this cancer. By identifying and developing inhibitors that can block the activity of CHD1L, the researchers aim to create new treatment options for patients with metastatic colorectal cancer. The study involves analyzing tumor samples from patients to understand how CHD1L contributes to cancer progression and to test potential drug candidates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic colorectal cancer who have not responded well to standard treatments.
Not a fit: Patients with early-stage colorectal cancer or those whose cancer is not driven by CHD1L may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective new treatments for patients with metastatic colorectal cancer.
How similar studies have performed: While targeting specific oncogenes is a growing area of research, this particular approach to inhibit CHD1L is novel and has not been extensively tested in clinical settings.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Labarbera, Daniel V. — University of Colorado Denver
- Study coordinator: Labarbera, Daniel V.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.